A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This study will compare RC48-ADC to physician choice standard treatment. Participants must
have HER2-low breast cancer ，previous use of anthracyclines, and have been treated with one
or two systemic chemotherapy regimens following recurrence/metastasis.